Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse.
The use of antagonists of N-methyl-D-aspartate (NMDA) receptors, or the administration of inhibitors of the synthesis or of the release of excitatory amino acids, enables the analgesic drug-dependence associated with chronic daily migraine to be overcome without any physical abstinence sign. Follow-up period indicates that negative modulators of excitatory amino-acid function can induce a stable benefit. The persistent benefit is seemingly due to an inhibitory effect on the process underlying the hyperalgesia state which is a crucial feature of migraine. It can also be suggested that the antagonist activity at NMDA receptor might play a role in very severe non-opioid analgesic drug dependence.
Nicolodi
M
M
Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache, University of Florence, Italy.
Del Bianco
P L
PL
Sicuteri
F
F
D000085:Acetates / Q000494:pharmacology; D000328:Adult; D000588:Amines; D002908:Chronic Disease; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D007649:Ketamine / Q000627:therapeutic use; D000077213:Lamotrigine; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D009293:Opioid-Related Disorders / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control; D014227:Triazines / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D014227:Triazines; D005680:gamma-Aminobutyric Acid; D007649:Ketamine; D000077206:Gabapentin; D000077213:Lamotrigine